Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study

Apathy in Parkinson Disease Clinical Trial

Official title:

Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01020682
• Other study ID #: APATHIE
• Status: Recruiting
• Phase: N/A
• First received: November 24, 2009
• Last updated: November 24, 2009
• Start date: January 2005
• Est. completion date: June 2011

Study information

• Verified date: November 2009
• Source: University Hospital, Grenoble
• Contact: Krack Paul, MD
• Phone: 0476765791
• Email: paul.krack[@]ujf-grenoble.fr
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Observational

Clinical Trial Summary

Apathy has been reported to occur after subthalamic nucleus stimulation (STN-DBS), a treatment of motor complications in advanced Parkinson's disease (PD). It is not known whether postoperative apathy is related to dopamine withdrawal or a side effect of STN DBS. The researchers investigated potential predictors of apathy, and the effect of dopamine agonist treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: June 2011
• Est. primary completion date: February 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Parkinson disease

Exclusion Criteria:

• Mattis scale < 130

• Beck scale > 20

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Apathy in Parkinson Disease
• Parkinson Disease

Locations

Country	Name	City	State
France	Hopital neurologique	Lyon

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Grenoble	Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France,